axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • HTLV-1
StabCFTR
8 September 2021
REEFPULSE
30 June 2021

HTLV-1

HTLV-1

Novel therapeutic strategy to fight adult T-cell leukemia

Available technology

Desired partnership(s)

  • Licensing

IP

  • Patent

Establishment(s)

  • University of Montpellier
  • National Center for Scientific Research

Laboratory(ies)

  • Infectiology Research Institute of Montpellier (IRIM - UMR 9004)

Keywords

  • Rare disease
  • Adult T-cell Leukemia (ATL)
  • HTLV-1

Context

Adult T-cell leukemia (ATL) is a rare and very aggressive lymphoproliferative disease caused by T cells infected with the HTLV-1 virus. Among individuals infected with the HTLV-1 virus, 3 to 5% will develop ATL in adulthood after a prolonged latency of 30 to 50 years, representing about 450,000 to 750,000 patients worldwide with a distribution in endemic areas corresponding to HTLV-1 infection. The prevalence of this pathology is not clearly defined and would probably be underestimated with an increase in incidence in non-endemic areas.
The prognosis for ATL is extremely low with an average survival of a few months for the majority of cases. Current treatments for ATL have limited long-term efficacy and therefore there is a real unmet medical need for the treatment of ATL.

Benefits

The technology developed is based on innovative therapeutic small molecules capable of inhibiting the transformation and proliferation of HTLV-1-infected cells.

Applications

This new therapeutic approach would improve the effectiveness of current ATL treatments and/or propose new ATL treatments.
The technology developed could also present applications for other indications such as other pathologies associated with HTLV-1 infection (TSP/HAM myelopathy, uveitis, infectious dermatitis, myositis or polymyositis) but also more broadly in oncology.

AVAILABLE TECHNOLOGY | Rare disease – Adult T-cell Leukemia (ATL) – HTLV-1

Share
0

Related posts

8 September 2021

StabCFTR


En savoir +
23 June 2021

GEOSOTECH


En savoir +
23 June 2021

ACUSURGICAL


En savoir +
© 2022, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French